Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
The dual targeting of GLP-1/GLP-2 and GIP receptors is hypothesized to enhance satiety, regulate glucose metabolism, and support tissue repair in metabolic disorders
Its very safe
Dose reduction as weight targets are reached Phase 3 trial protocols allow dose reduction when a participant's BMI drops to 22 kg/m or below, or when there is perceived excessive weight loss
Therefore, glucose status should be carefully evaluated prior to initiating tesamorelin treatment
Inject on the same day each week but allow flexibility of plus or minus 2 days
US$ 23.12
US$ 21.10
US$ 22.31
US$ 24.31
US$ 25.06
US$ 23.02
US$ 21.36
US$ 29.24
